Yeah, but if investors/traders (our new professional investors will not be shy of trading or rather "recalibrating portfolios", for all the share register defence against takeover talk) have been following the releases, they should have been aware that the results always were going finalised for realease to mkt Q3 CY24 and FDA application Q4 CY24.
That they've completed the physcial aspect of the FDA comparator study successfully and confirmed FDA application on track for Q4 CY24, is a small positive risk-reducing announcement and that they've rather confidently predicted "clearance for Remplir expected in Q1 CY25" in a bold assured statement for investors.
I actually was surprised to read this:
"the Company remains on track to submit its US 510(K) market authorisation application in
Q4 CY24and progression into sales soon thereafter" (my embolden)
That's unusally brazen for these guys and perhaps gives suggestion of them ALL (
) being 'excited' and perhaps having something like the BioHOrizons style deal in negogiation - the company of old far too tardy 'standalone' to progress to sales "soon thereafter".
